BioSpace News Archive

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock,

he Honourable Ginette Petitpas Taylor, federal Minister of Health will take part in the commemoration of World AIDS Day.

With the World AIDS Day 2018 Red Ribbon Campaign in full swing, DKT International, a global non-profit dedicated to family planning and HIV/AIDS prevention, continues its efforts to curb the spread of HIV/AIDS through its country and regional initiatives to increase condom use.

The IRS has announced an extension to the deadline for furnishing employee statements (Form 1095) for the Affordable Care Act. These extensions pertain to sections 6055 and 6056 of the Internal Revenue Code

TILT Holdings Inc. (“TILT” or the “Company”), a vertically-integrated technology and infrastructure platform delivering a comprehensive range of products and services across the cannabis industry, today released an open letter from Alex Coleman, Chairman and Chief Executive Officer of TILT.

United Urology Group is pleased to announce that effective December 1st, three of the premier urology group practices in Colorado - Advanced Urology, Alpine Urology and Foothills Urology, will become affiliates.

Today eHealth, Inc. (NASDAQ: EHTH) (eHealth.com) released a report analyzing costs and trends among eHealth customers in the first half of the 2019 open enrollment period under the Affordable Care Act (ACA), which began November 1 and is scheduled to run through December 15, 2018.

Aurinia Pharmaceuticals Inc. today announced that it has entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to US$30,000,000.

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin.